Atnahs Pharma launches €260 million add-on term loan B at 99 OID

By Sara Rosenberg

New York, Feb. 10 – Atnahs Pharma UK Ltd. launched on Monday its fungible €260 million add-on covenant-lite term loan B due Aug. 7, 2026 with price talk of Euribor plus 500 basis points with a 0% floor and an original issue discount of 99, according to a market source.

Barclays, Credit Suisse and HSBC are the physical bookrunners on the deal. KKR Capital Markets, Investec, MUFG and NatWest Markets are bookrunners.

Commitments are due at 7 a.m. ET on Feb. 24.

Proceeds will be used to fund the acquisition of a product portfolio from AstraZeneca and a single product from a large pharma company, and to pay related fees and expenses.

Including the add-on, the term loan will total €614 million.

Atnahs Pharma is a Basildon, U.K., specialty pharmaceutical business focused on the acquisition, development and marketing of mature branded medicines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.